Jim Shi Xiang Qin

Title: Jim Shi Xiang Qin: Innovator in Immunotherapy

Introduction

Jim Shi Xiang Qin is a prominent inventor based in Seattle, WA (US). He has made significant contributions to the field of immunotherapy, particularly in T cell modulation. His innovative approaches aim to enhance the efficacy of cancer treatments through advanced methodologies.

Latest Patents

Jim Shi Xiang Qin holds a patent titled "Methods and combinations for treatment and T cell modulation." This patent focuses on methods, compositions, and uses involving immunotherapies, such as adoptive cell therapy and T cell therapy. The patent also discusses the use of immunomodulatory compounds, including structural or functional analogs of thalidomide and inhibitors of E3-ubiquitin ligase. The methods and compositions provided in this patent are designed to improve the activity, efficacy, persistence, and proliferation of T cells for adoptive cell therapy.

Career Highlights

Jim Shi Xiang Qin is currently associated with Juno Therapeutics GmbH, where he continues to advance his research in immunotherapy. His work has been instrumental in developing innovative treatment options for patients with cancer. With a focus on T cell therapies, he has contributed to the growing field of personalized medicine.

Collaborations

Jim has collaborated with notable colleagues, including Jens Hasskarl and Stanley R Frankel. These partnerships have fostered a collaborative environment that enhances the development of cutting-edge therapies.

Conclusion

Jim Shi Xiang Qin is a key figure in the field of immunotherapy, with a focus on T cell modulation. His innovative patent and ongoing work at Juno Therapeutics GmbH highlight his commitment to improving cancer treatment methodologies. His contributions are paving the way for advancements in personalized medicine and immunotherapy.